tris-(3-fluoro-phenyl)-methanol | 379-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: tris-(3-fluoro-phenyl)-methanol
• 英文别名: Hydroxy-tris-(3-fluor-phenyl)-methan；Tris-(3-fluor-phenyl)-methanol；Tris(3-fluorophenyl)methanol
• CAS: 379-44-2
• 化学式: C₁₉H₁₃F₃O
• 分子量: 314.307
• InChiKey: UXOPBLFPZILVFW-UHFFFAOYSA-N

物化性质

• 熔点：
  118.5-119 °C
• 沸点：
  406.2±40.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tris-(3-fluoro-phenyl)-methanol 在 氯化亚砜 作用下， 生成 3,3',3''-trifluoro-trityl chloride
  参考文献：
  名称：

  Bartroli; Alguero; Boncompte, Arzneimittel-Forschung/Drug Research, 1992, vol. 42, # 6, p. 832 - 835

  摘要：

  DOI：
• 作为产物：
  描述：

  间溴氟苯 、 3,3'-二氟二苯甲酮 在 magnesium 作用下， 生成 tris-(3-fluoro-phenyl)-methanol
  参考文献：
  名称：

  Bartroli; Alguero; Boncompte, Arzneimittel-Forschung/Drug Research, 1992, vol. 42, # 6, p. 832 - 835

  摘要：

  DOI：

文献信息

• Bartroli; Alguero; Boncompte, Arzneimittel-Forschung/Drug Research, 1992, vol. 42, # 6, p. 832 - 835
  作者：Bartroli、Alguero、Boncompte、Forn

  DOI：——

  日期：——
• The Dissociation of Hexaarylethanes. XVI.¹ Alkyl and Halogen Derivatives
  作者：C. S. Marvel、H. W. Johnston、J. W. Meier、T. W. Mastin、John Whitson、Chester M. Himel

  DOI：10.1021/ja01234a023

  日期：1944.6
• Novel Inhibitors of the Gardos Channel for the Treatment of Sickle Cell Disease
  作者：Grant A. McNaughton-Smith、J. Ford Burns、Jonathan W. Stocker、Gregory C. Rigdon、Christopher Creech、Susan Arrington、Tara Shelton、Lucia de Franceschi

  DOI：10.1021/jm070663s

  日期：2008.2.1

  Sickle cell disease (SCD) is a hereditary condition characterized by deformation of red blood cells (RBCs). This phenomenon is due to the presence of abnormal hemoglobin that polymerizes upon deoxygenation. This effect is exacerbated when dehydrated RBCs experience a loss of both water and potassium salts. One critical pathway for the regulation of potassium efflux from RBCs is the Gardos channel, a calcium-activated potassium channel. This paper describes the synthesis and biological evaluation of a series of potent inhibitors of the Gardos channel. The goal was to identify compounds that were potent and selective inhibitors of the channel but had improved pharmacokinetic properties compared to 1, Clotrimazole. Several triarylamides such as 10 and 21 were potent inhibitors of the Gardos channel (IC50 of < 10 nM) and active in a mouse model of SCD. Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.